<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30150157</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>05</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-2157</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>44</Volume>                    <Issue>11</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>11</Month>                    </PubDate>                </JournalIssue>                <Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title>                <ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Non-histopathological parameters associated with upgrade of breast tumours yielding a core biopsy report of histological grade 2 ductal no special type to grade 3 on excision.</ArticleTitle>            <Pagination>                <MedlinePgn>1720-1724</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0748-7983(18)31181-8</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2018.07.002</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE">The aim of the study was to identify clinical, radiological and immuno-histochemical factors that may help predict upgrade of invasive ductal cancers of no special type (IDC-NST) with a core biopsy grade of 2 to grade 3 on final histology.</AbstractText>                <AbstractText Label="METHODS">A prospectively maintained database of ultrasound visible solid masses was used to identify lesions yielding a core biopsy result of IDC-NST grade 2 who underwent immediate surgery yielding a grade 2 or grade 3 tumour. Associations were sought between the source of patient (screening/symptomatic), core biopsy receptor status and imaging findings and the grade of the excision specimen tumour. Statistical analysis, which included the chi-squared test, ROC curves and Cox regression analysis, was used to compare upgrade vs no upgrade for each factor.</AbstractText>                <AbstractText Label="RESULTS">463 IDC-NST breast cancers of core biopsy grade 2 gave 344 grade 2 and 119 grade 3 tumours at excision. Factors significantly associated with upgrade were large ultrasound (US) size, hyperechogencity, stiffness at shearwave elastography (SWE), calcification on mammography and oestrogen receptor (ER) and progesterone receptor (PR) negativity. Patient source, Human epidermal growth factor receptor 2 (HER-2) status, ultrasound (US) distal effect and mammographic spiculation were not significantly associated with chance of upgrade. On multivariate analysis, only US size maintained statistical significance.</AbstractText>                <AbstractText Label="CONCLUSION">Oncologists and surgeons should be aware that lesions with a core biopsy diagnosis of grade 2 IDC-NST measuring over 15 mm on US have a 37% chance of being grade 3 on excision and this should be considered when deciding pre-operative management.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ahmeidat</LastName>                    <ForeName>Hassen</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Ninewells Hospital, NHS Tayside, United Kingdom. Electronic address: h.ahmeidat@nhs.net.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Purdie</LastName>                    <ForeName>Colin</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Histopathology, Ninewells Hospital, NHS Tayside, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jordan</LastName>                    <ForeName>Lee</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Histopathology, Ninewells Hospital, NHS Tayside, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fleming</LastName>                    <ForeName>Dawn</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Histopathology, Ninewells Hospital, NHS Tayside, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McCullough</LastName>                    <ForeName>Jean</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Histopathology, Ninewells Hospital, NHS Tayside, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Evans</LastName>                    <ForeName>Andrew</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>University of Dundee, NHS Tayside, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Eur J Surg Oncol</MedlineTA>            <NlmUniqueID>8504356</NlmUniqueID>            <ISSNLinking>0748-7983</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D062005" MajorTopicYN="N">Biopsy, Large-Core Needle</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008327" MajorTopicYN="N">Mammography</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016217" MajorTopicYN="N">Ultrasonography, Mammary</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Clinical features</Keyword>            <Keyword MajorTopicYN="Y">Histological grade</Keyword>            <Keyword MajorTopicYN="Y">Invasive carcinoma of no special type</Keyword>            <Keyword MajorTopicYN="Y">Neoadjuvant chemotherapy</Keyword>            <Keyword MajorTopicYN="Y">Radiological features</Keyword>            <Keyword MajorTopicYN="Y">Receptor status</Keyword>            <Keyword MajorTopicYN="Y">Upgrade rate</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30150157</ArticleId>            <ArticleId IdType="pii">S0748-7983(18)31181-8</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejso.2018.07.002</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>